CHANCE-2 clinical trial including individuals mainly carriers of the CYP2C19 loss-of-function alleles, ticagrelor and aspirin was superior to clopidogrel and aspirin in reducing the risk of subsequent stroke and did not increase the risk of severe or moderate bleeding. Here, CYP2C19 is linked to Stroke.